GREENWICH LIFESCIENCES, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.7 USD | -5.01% |
|
-2.34% | +58.75% |
| Jul. 01 | Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2000 Index | CI |
| Jul. 01 | Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 3000E Index | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 463.3 | 319.3 | 195.3 | 135.2 | 215.1 | - |
| Enterprise Value (EV) 1 | 463.3 | 319.3 | 195.3 | 135.2 | 215.1 | 215.1 |
| P/E ratio | -182 x | -69.5 x | -24.9 x | -15.2 x | -22.3 x | -23.9 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 12,704 | 13,123 | 12,848 | 12,848 | 12,880 | - |
| Reference price 2 | 36.47 | 24.33 | 15.20 | 10.52 | 16.70 | 16.70 |
| Announcement Date | 3/31/21 | 3/21/22 | 3/31/23 | 4/15/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -1.864 | -4.598 | -8.04 | -9.328 | 10.19 | 10.2 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -4.571 | -7.825 | -8.892 | -10.12 | -10.2 |
| Net income 1 | -3.425 | -1.863 | -4.571 | -7.825 | -8.892 | -10.12 | -10.2 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -1.522 | -0.2000 | -0.3500 | -0.6100 | -0.6900 | -0.7500 | -0.7000 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 5/29/20 | 3/31/21 | 3/21/22 | 3/31/23 | 4/15/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.377 | -1.989 | -0.7733 | -2.383 | -2.895 | -2.241 | -1.748 | -2.503 | -2.836 | - | 2.55 | 2.55 | 2.55 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.361 | -1.97 | -0.7461 | -2.319 | -2.791 | -2.125 | -1.628 | -2.392 | -2.747 | - | -2.55 | -2.55 | -2.55 |
| Net income 1 | -2.361 | -1.97 | -0.7461 | -2.319 | -2.791 | -2.125 | -1.628 | -2.392 | -2.747 | - | -2.55 | -2.55 | -2.55 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1800 | -0.1500 | -0.0600 | -0.1800 | -0.2200 | -0.1700 | -0.1300 | -0.1900 | -0.2100 | -0.1900 | -0.2000 | -0.1900 | -0.1700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/21/22 | 5/20/22 | 8/15/22 | 11/14/22 | 3/31/23 | 5/22/23 | 8/21/23 | 10/19/23 | 4/15/24 | 5/20/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 5/29/20 | 3/31/21 | 3/21/22 | 3/31/23 | 4/15/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
16.7
USD
Average target price
36
USD
Spread / Average Target
+115.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +58.75% | 215M | |
| +3.79% | 95.71B | |
| +5.66% | 41.64B | |
| -13.20% | 32.7B | |
| +79.53% | 28.65B | |
| -16.02% | 15.38B | |
| -8.17% | 12.97B | |
| -13.35% | 11.47B | |
| +160.91% | 9.92B | |
| -56.29% | 9.07B |
- Stock Market
- Equities
- GLSI Stock
- Financials Greenwich LifeSciences, Inc.
